More than 15 million people in the United States have been diagnosed with chronic obstructive pulmonary disease (COPD), the nation’s third leading cause of death. Alarmingly, an estimated 12 million more Americans suffering with COPD are undiagnosed, leaving them vulnerable to progression of disease, poor quality of life, inability to work, significant comorbidities, and death. New strategies for diagnosing and stratifying risk in patients with COPD, along with new pathways for therapeutic interventions, provide the framework for improved management. Spirometry, the single most important tool in assessing airflow limitation, is still underused in primary care. Poor patient adherence to therapies is of paramount concern, and the 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines emphasize the need to work with patients to ensure they are comfortable and competent with the use of prescribed inhaler devices.
1.00 ANCC contact hours
1.00 contact hours of pharmacotherapy credit
1.00 AAPA Category 1 CME credits
Video roundtable discussion
Educate nurse practitioners (NPs) and physician assistants (PAs) on diagnosing and stratifying risk in patients with symptoms of COPD, applying new guidelines to optimize treatment for patients with COPD, and improving adherence to therapies by working with patients to ensure correct use of prescribed devices for inhaled medications; as well as to reduce COPD exacerbations, hospitalizations, and readmissions.
After completing this activity, participants should be better able to:
- Identify patient risk factors and diagnostic clues that suggest COPD
- Use validated clinical tools, including spirometry, to confirm COPD, assess symptom severity, and complete risk stratification
- Develop guideline-based treatment strategies to minimize exacerbations and hospitalizations while taking individual patient preferences and factors into account
NPs and PAs
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and jointly provided by Practicing Clinicians Exchange.
Contact hours: 1.0, which are eligible for 1.0 pharmacology credits
Course director: Jason Worcester, MD, Boston University School of Medicine
CNE course advisor: Claire Murphy, MSN, NP-C, Boston University School of Medicine
This program has been reviewed and is approved for a maximum of 1.00 hour(s) of AAPA Category 1 CME credit by the PA Review Panel. Approval is valid for 1 year from the issue date of March 6, 2017. Participants may submit the post-test at any time during that period.
This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This educational activity is supported by an educational grant from Sunovion Pharmaceuticals Inc.
The opinions or views expressed in this continuing education activity are those of the faculty and do not necessarily reflect the opinions or recommendations of Boston University School of Medicine, Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices is being discussed.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration.
Dr Han: consultant: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sunovion.
Dr Fiel: consultant: Gilead, Novartis; data and safety monitoring board: CFF; grant/research support: CFF, Gilead, Novartis, Vertex; speakers' bureau: Genentech, Gilead, Novartis, Pfizer.
Ms Stempek has nothing to disclose with regard to commercial interests.
The Planning Committee for this activity included Claire Murphy, MSN, NP-C, Jody Walker, MS, Julie L. White, MS, and Jason Worcester, MD, of Boston University School of Medicine; Patti-Ann Collins, DNP, MSN, MBA, RN (Lead Nurse Planner), of Healthcare Advocacy Services; Mark Christiansen, PhD, PA-C, of University of the Pacific; and Ruth Cohen and Warren Beckman of Practicing Clinicians Exchange. None of the aforementioned members of the Planning Committee have any significant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Listen to the presentation and study the program slides
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: March 6, 2017
Expiration date: March 5, 2018
COURSE VIEWING REQUIREMENTS
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, or Windows 7, 8, or 10
Google Chrome 18.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 13.0+ for Windows, Mac OS, or Linux
Safari 4.0+ for Mac OSX 10.5+
© 2018 Practicing Clinicians Exchange. All Rights Reserved. SPCE90416